What does RPA stand for?

Recombinant Protective Antigen

This definition appears very rarely and is found in the following Acronym Finder categories:

Science, medicine, engineering, etc.

Other Resources:

<< Previous	Abbreviation Database Surfer		Next >>
Rate Plan Analysis Ratepayer Advocate (NJ, USA) Rationalist Press Association Ravenswood Physicians Associates (Chicago, IL) Reach Pollution Assessment Real Property Administrator (property management certificate; Canada) Real Property Assessment Reasonable and Prudent Alternative Rebirthing Psychotherapy Association Receiver Performance Analysis (KILTING)		Recommended Pricing Adjustment Reconciling Pentecostal Assembly Records Preservation and Access Rectangular Patch Antenna Recursive Partitioning Analysis Recycled Paperboard Alliance Red Pine Ambassadors (Douglass College) Reduced Pressure Assembly (backflow prevention device used in water systems) Redundancy Payments Act Redundant Parallel Architecture (General Electric Company)

Samples in periodicals archive:

government another site where recombinant protective antigen (rPA) anthrax vaccine, which is under Phase II development, can be produced.

United states : Emergent Expands Manufacturing and Development ...

The Detrick team created a genetically modified version — a skillful fake — called the recombinant protective antigen, or rPA.

Anthrax suspect was a prolific scientific author

The Detrick team created a genetically modified version — a skillful fake — called the recombinant protective antigen, or rPA.

Anthrax suspect was a prolific scientific author

On other fronts, researchers now have identified and isolated all three of the toxins of anthrax: lethal toxic, edema factor, and recombinant protective antigen.

High stakes, fast track: Bio R&D at a full gallop

The anthrax vaccine candidate is composed of the double-mutant recombinant protective antigen (dmPA), which has been genetically engineered for improved stability.

NIAID to Fund Development of Emergent BioSolutions' Advanced Anthrax ...

Food and Drug Administration (FDA) a Development Plan for the company s Recombinant Protective Antigen (rPA) anthrax vaccine candidate.

united states : Emergent BioSolutions Submits to FDA Development Plan ...

It is the same technology VaxGen is using to develop its recombinant Protective Antigen anthrax vaccine, rPA102, under contract from the National Institute of Allergy and Infectious Diseases (NIAID).

VaxGen finalizes commercial rights to anthrax vaccine

government for our recombinant protective antigen anthrax vaccine candidate; our plans to expand our manufacturing facilities and capabilities; the rate and degree of market acceptance and clinical utility of our products; our ongoing and planned development programs, preclinical studies and clinical trials; the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and other factors identified in the company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2009 and subsequent reports filed with the SEC.

Emergent BioSolutions Meets With FDA To Review Regulatory Strategy ...